Paul Friedman, M.D., Chief Executive Officer of Madrigal, stated, “The recent submission of the resmetirom NDA represents an important milestone for Madrigal and the NASH community. Based on the depth and breadth of efficacy and safety data we have generated through the MAESTRO program, I believe we are well-positioned to support the FDA’s review of resmetirom. In parallel with our regulatory activities, our Commercial and Medical Affairs teams are intently focused on preparing for a potential first-to-market launch in the U.S.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MDGL:
- Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results
- MDGL Earnings this Week: How Will it Perform?
- Madrigal Pharmaceuticals completes submission of NDA to U.S. FDA for resmetirom
- Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis
- B. Riley biotechnology analysts to hold an analyst/industry conference call